Curcumin increases crizotinib sensitivity through the inactivation of autophagy via epigenetic modulation of the miR-142-5p/Ulk1 axis in non-small cell lung cancer
Cancer Biomarkers · 19.05.2022 · 34 (2) · 297-307
DOI: 10.3233/cbm-210282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, erschienen am 19.05.2022. Verfasst von Yu-Zheng He und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Curcumin, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Drug resistance is a critical factor responsible for the recurrence of non-small cell lung cancer (NSCLC). Previous studies suggest that curcumin acts as a chemosensitizer and radiosensitizer in human malignancies, but the underlying mechanism remains elusive. In the present study, we explored how curcumin regulates the expression of miR-142-5p and sensitizes NSCLC cells to crizotinib. We found that miR-142-5p is significantly downregulated in NSCLC tissue samples and cell lines. Curcumin could increase crizotinib cytotoxicity by epigenetically restoring the expression of miR-142-5p. Furthermore, curcumin treatment suppressed the expression of DNA methylation-related enzymes, including DNMT1, DNMT3A, and DNMT3B, in NSCLC cells. In addition, the upregulation of miR-142-5p expression increased crizotinib cytotoxicity and induced apoptosis in tumor cells in a similar manner to that of curcumin. Strikingly, miR-142-5p overexpression suppressed crizotinib-induced autophagy in A549 and H460 cells. Mechanistically, miR-142-5p inhibited autophagy in lung cancer cells by targeting Ulk1. Overexpression of Ulk1 abrogated the miR-142-5p-induced elevation of crizotinib cytotoxicity in A549 and H460 cells. Collectively, our findings demonstrate that curcumin sensitizes NSCLC cells to crizotinib by inactivating autophagy through the regulation of miR-142-5p and its target Ulk1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Medical Intensive Care Unit, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.
- Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei, China.
- Department of Medical Imaging, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Respiratory and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Thoracic Surgery, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Zitieren
APA
He, Y. Z., Yu, S. L., Li, X. N., Bai, X. H., Li, H. T., Liu, Y. C., Lv, B. L., Zhao, X. M., Wei, D., Zhang, H. L., Li, F. N., Li, G., & Li, S. (2022). Curcumin increases crizotinib sensitivity through the inactivation of autophagy via epigenetic modulation of the miR-142-5p/Ulk1 axis in non-small cell lung cancer. Cancer Biomarkers, 34(2), 297-307. https://doi.org/10.3233/cbm-210282
Vancouver
He YZ, Yu SL, Li XN, Bai XH, Li HT, Liu YC, et al. Curcumin increases crizotinib sensitivity through the inactivation of autophagy via epigenetic modulation of the miR-142-5p/Ulk1 axis in non-small cell lung cancer. Cancer Biomarkers. 2022;34(2):297-307. doi:10.3233/cbm-210282
BibTeX
@article{He2022,
author = {He, Yu-Zheng and Yu, Shan-Ling and Li, Xiao-Ning and Bai, Xian-Hua and Li, Hai-Tao and Liu, Yan-Chao and Lv, Bao-Lei and Zhao, Xiu-Min and Wei, Dong and Zhang, He-Lin and Li, Fan-Nian and Li, GuoLei and Li, Shuai},
title = {Curcumin increases crizotinib sensitivity through the inactivation of autophagy via epigenetic modulation of the miR-142-5p/Ulk1 axis in non-small cell lung cancer},
journal = {Cancer Biomarkers},
year = {2022},
volume = {34},
number = {2},
pages = {297--307},
doi = {10.3233/cbm-210282}
}
EUVIMED